18.207.157.152
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Journal Scan
Retina

Quick treatment with intravitreal antibiotics key to good outcomes for endophthalmitis

Posted on January 27, 2022

The incidence of acute endophthalmitis after intravitreal injection of bevacizumab (IVB) is very low, with a short time between injection and presentation. Timely treatment with intravitreal antibiotics and early pars plana vitrectomy is important to maximize outcomes, according to a study.

Of 28,085 IVB injections performed during this retrospective study period, 9 eyes (9 patients) developed acute post IVB endophthalmitis, for an overall incidence of 0.032% (95% CI, 0.01-0.06) (3.2 in 10,000 injections). Three cases were culture-positive (staphylococcus epidermidis).

There was a mean time of 2.77 ± 1.25 days between IVB injection and presentation of endophthalmithis and a mean of 4 ± 1.5 previous IVB injections before developing endophthalmitis.

The mean best corrected visual acuity before IVB injection was 1.18 ± 0.62 logMAR and 2.5 ± 0.42 logMAR at the presentation of endophthalmithis. At 3 months post-treatment of endophthalmithis the mean best corrected visual acuity was 1.94 ± 0.88 logMAR.

One eye developed phthisis bulbi.

Reference
Karimi S, Fakhri N, Ansari I, et al. Incidence and management of acute endophthalmitis after intravitreal injection of bevacizumab. Int Ophthalmol. 2022; doi: 10.1007/s10792-021-02180-7. Epub ahead of print. PMID: 35079940.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-